Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: PIPELINE ANALYSIS PART 09: MARKET SEGMENTATION BY DRUG CLASS • Segmentation by drug class • Comparison by drug class • Somatostatin analogs – Market size and forecast 2017-2022 • GH receptor antagonists – Market size and forecast 2017-2022 • Dopamine agonists – Market size and forecast 2017-2022 • Recombinant human IGF-1 – Market size and forecast 2017-2022 • Market opportunity by product PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 14: MARKET TRENDS • Growing popularity of drugs over surgeries • Focus on long-acting novel formulations PART 15: VENDOR LANDSCAPE • Overview • Landscape disruption PART 16: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Ipsen • Novartis • Pfizer PART 17: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Parent market Exhibit 02: Global acromegaly and gigantism drugs market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global acromegaly and gigantism drugs market 2017-2022 ($ mn) Exhibit 09: Global acromegaly and gigantism drugs market: Year-over-year (YoY) growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Pipeline landscape by development phase Exhibit 19: Key clinical trials for global acromegaly and gigantism drugs market Exhibit 20: Segmentation of global acromegaly and gigantism drugs market by drug class 2017-2022 (%) Exhibit 21: Comparison by drug class Exhibit 22: Somatostatin analogs – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Somatostatin analogs – YoY growth 2018-2022 (%) Exhibit 24: GH receptor antagonists – Market size and forecast 2017-2022 ($ mn) Exhibit 25: GH receptor antagonists – YoY growth 2018-2022 (%) Exhibit 26: Dopamine agonists – Market size and forecast 2017-2022 ($ mn) Exhibit 27: Dopamine agonists – YoY growth 2018-2022 (%) Exhibit 28: Recombinant human IGF-1 – Market size and forecast 2017-2022 ($ mn) Exhibit 29: Recombinant human IGF-1 – YoY growth 2018-2022 (%) Exhibit 30: Market opportunity by product Exhibit 31: Customer landscape Exhibit 32: Segmentation of global acromegaly and gigantism drugs market by geography 2017-2022 (%) Exhibit 33: Regional comparison Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 35: Americas – YoY growth 2018-2022 (%) Exhibit 36: Top three countries in Americas Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 38: EMEA – YoY growth 2018-2022 (%) Exhibit 39: Top three countries in EMEA Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 41: APAC – YoY growth 2018-2022 (%) Exhibit 42: Top three countries in APAC Exhibit 43: Market opportunity Exhibit 44: Percentage increase in GDI of India, China, and US for 2011-2016 Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Ipsen – Vendor overview Exhibit 51: Ipsen – Business segments Exhibit 52: Ipsen – Organizational developments Exhibit 53: Ipsen – Geographic focus Exhibit 54: Ipsen – Segment focus Exhibit 55: Ipsen – Key offerings Exhibit 56: Ipsen– Key customers Exhibit 57: Novartis – Vendor overview Exhibit 58: Novartis – Business segments Exhibit 59: Novartis – Organizational developments Exhibit 60: Novartis – Geographic focus Exhibit 61: Novartis – Segment focus Exhibit 62: Novartis – Key offerings Exhibit 63: Pfizer – Vendor overview Exhibit 64: Pfizer – Business segments Exhibit 65: Pfizer – Organizational developments Exhibit 66: Pfizer – Geographic focus Exhibit 67: Pfizer – Segment focus Exhibit 68: Pfizer – Key offerings Exhibit 69: Pfizer – Key customers

Ipsen, Novartis, and Pfizer